Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CCR9 | P51686 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30802846 | 1.00 | KDM4E (0.43) | KDM4EL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL12303328 | 0.83 | KDM4E (0.41) | KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12266677 | 0.83 | KDM4E (0.41) | KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15986681 | 0.83 | L3MBTL1 (0.41) | KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16544500 | 0.83 | SMN1; SMN2 (0.41) | KDM4EL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL16368521 | 0.83 | KDM4E (0.41) | KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10272809 | 0.83 | PDE10A (0.46) | KDM4EL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL13718708 | 0.81 | CCR9 (0.37) | CCR9 | |
| SCHEMBL619744 | 0.81 | CCR9 (0.40) | ALDH1A1NPC1RAB9ACCR9CA2 | |
| SCHEMBL13188065 | 0.81 | CCR9 (0.40) | CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| EP-4177249-A1 | IMMUNOMODULATOR | Hitgen Inc. (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023004163-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20210309679-A1 | BISPHOSPHONATE DRUG CONJUGATES | GUANGZHOU OTHROTX CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| WO-2021113557-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20080108630-A1 | SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7323480-B2 | Substituted triazoles as modulators of PPAR and methods of their preparation | METABOLEX, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | KDM4E 3386/4885L3MBTL1 2504/4885ALDH1A1 2674/4885 |
| US-20210309679-A1 | BISPHOSPHONATE DRUG CONJUGATES | SOST, TGFB1, TGFB2 | KDM4E 4020/4885L3MBTL1 3776/4885ALDH1A1 2283/4885 |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | KDM4E 4343/4885L3MBTL1 2174/4885ALDH1A1 1072/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885L3MBTL1 1131/4885ALDH1A1 344/4885 |
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, LPAR5, S1PR2 | KDM4E 383/4885L3MBTL1 4503/4885ALDH1A1 1161/4885 |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | SARS1, NSUN3, GTF3C4 | KDM4E 1735/4885L3MBTL1 655/4885ALDH1A1 2958/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | KDM4E 1886/4885L3MBTL1 3603/4885ALDH1A1 1035/4885 |
| US-20090076064-A1 | Compounds | CEL, PLA2G2D, CCKBR | KDM4E 2862/4885L3MBTL1 3160/4885ALDH1A1 114/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | KDM4E 2302/4885L3MBTL1 3237/4885ALDH1A1 1649/4885 |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | NOX1, NOX3, ELANE | KDM4E 3928/4885L3MBTL1 2597/4885ALDH1A1 1110/4885 |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | KDM4E 1336/4885L3MBTL1 4148/4885ALDH1A1 2777/4885 |
| US-20080108630-A1 | SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, GPR119 | KDM4E 3503/4885L3MBTL1 3746/4885ALDH1A1 2436/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885L3MBTL1 721/4885ALDH1A1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.